Silo Pharma, Inc. (SILO) has received a positive indication from the European Patent Office for a patent aimed at preventing stress-related disorders, a significant advancement for its therapeutic pipeline. The patent, which Silo holds under an exclusive license from Columbia University, focuses on a novel approach using serotonin 4 receptor agonists to build resilience against stress before it manifests, contrasting with traditional treatments that primarily alleviate symptoms.
This development is crucial as stress-related psychiatric disorders, including PTSD, represent a large and largely underserved market. By shifting the focus from treatment to prevention, Silo Pharma positions itself to potentially transform mental health care. The company is also advancing multiple programs targeting conditions such as fibromyalgia, neuroinflammation, and multiple sclerosis, with key data readouts expected in 2026.
Investors should note that SILO’s stock has shown significant volatility, closing at $0.35 before surging to $0.59 in overnight trading, reflecting growing market interest in its innovative approach to CNS therapeutics.
Source: nasdaq.com